Articles on mid market.
5 articles from the Archer team on this topic.
Best onsite clinic companies for small and mid-sized employers (100–1,000 employees)
A 2026 buyer's guide to the best onsite, near-site, and direct-primary-care options for employers with 100 to 1,000 employees. How the models compare, why most 'onsite' vendors won't quote below 1,000 lives, and how a shared, part-time onsite clinic changes the math — with a side-by-side table of Archer Health, Marathon Health, Premise Health, Proactive MD, Hint, and Paladina.
How much does an onsite clinic cost? A 2026 pricing guide for employers with 100–1,000 employees
A plain-English breakdown of what an employer-sponsored onsite or shared clinic actually costs in 2026 — the three staffing models and their real per-employee price, what's included, how pass-through labs and pharmacy work, and how to calculate net cost after redirected claims. Built for self-funded employers with 100 to 1,000 employees, where a shared, part-time clinic changes the math.
Your 2026 health benefits renewal is up 11%. Here's where the money is leaking — and the one structural lever that still works.
Mid-market self-funded plans are getting renewal letters with 9–13% increases this year. Stop-loss premiums, specialty pharmacy, and high-cost claimants are doing most of the damage. Here's a CFO-grade breakdown of where the 11% comes from, the four levers HR teams are pulling in response, and why onsite primary care is the only one that compounds.
The 5,000-Employee Myth: How Mid-Market Companies Get Onsite Primary Care That Actually Works
For 30 years onsite clinics were a Fortune-500 perk because the math only worked at scale. New shared-clinic models break that floor. Here's how the economics work at 200, 500, and 1,000 employees — and why brokers are finally writing real proposals for sub-1,500 headcount.
For Twenty Years, Onsite Clinics Were a Benefit Only Giants Could Afford. That's Finally Over.
An HR director with 412 employees. Six years of trying to solve the same problem. Why the mid-market was disqualified — and what changed.